EGFR and non-small cell lung carcinoma: For instance, a combination of Let-7 and miR-34 mimic delivered to a Kras-Trp53 (Kras mutation-p53 deletion) NSCLC mouse model showed promising results, which improved further when complemented with EGFR inhibitor (erlotinib) [67,68].